Physician

John Mark Demay, MD

According to 2025 Medicare claims, John Demay, MD (NPI: 1366447294) practices dermatology in the Sioux City, IA-NE-SD market, with the plurality of this provider's patient population coming from Woodbury, IA. This provider's primary affiliated billing organization is DERMATOLOGY ASSOCIATES OF SIOUXLAND, PC (NPI: 1417088907; TIN: 461593021) and primary practice location at 51104-2425.

Demay's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 945 traditional Medicare patients, billed 9,962 HCPCS/CPT codes, and received $828,811 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 670 prescription claims across 296 beneficiaries totaling $58,329 in drug costs, led by Clobetasol Propionate (Clobetasol Propionate). Open Payments data shows 7 records totaling $118. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $262,736 to $828,811. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $81,804 and ending at $58,329. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,341	9,900	$262,736
2016	1,379	9,687	$253,539
2017	1,347	8,646	$247,902
2018	1,300	8,588	$262,550
2019	1,294	8,007	$271,720
2020	1,112	6,427	$246,723
2021	1,070	6,754	$338,597
2022	995	7,803	$547,576
2023	956	10,367	$857,017
2024	945	9,962	$828,811

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	344	930	$81,804
2016	350	1,041	$84,185
2017	316	849	$106,164
2018	341	751	$56,504
2019	307	779	$74,108
2020	292	769	$51,240
2021	306	734	$72,396
2022	273	647	$88,793
2023	290	614	$43,862
2024	296	670	$58,329

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
11102	Biopsy of related skin growth, first growth	161	206	$68
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	837	1,646	$58
17000	Destruction of precancer skin growth, 1 growth	388	556	$42
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	175	371	$39
17003	Destruction of precancer skin growth, 2-14 growths	274	1,300	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Clobetasol Propionate	Clobetasol Propionate	51	1,428	$3,017
Metronidazole	Metronidazole	29	990	$2,071
Gentamicin Sulfate	Gentamicin Sulfate	52	1,277	$1,676
Clindamycin Phosphate	Clindamycin Phosphate	40	1,210	$1,608
Triamcinolone Acetonide	Triamcinolone Acetonide	162	4,440	$803

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$118	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John Mark Demay, MD?

Tedicare shows public-source Medicare data for John Mark Demay, MD (NPI 1366447294), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John Mark Demay, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John Mark Demay, MD?

John Mark Demay, MD is linked to DERMATOLOGY ASSOCIATES OF SIOUXLAND, PC (billing NPI 1417088907) in the available physician profile data.

Does John Mark Demay, MD have Open Payments data?

John Mark Demay, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.